- Previous close
63.64 - Open
64.77 - Bid 63.88 x 700
- Ask 63.99 x 700
- Day's range
63.37 - 65.07 - 52-week range
62.55 - 170.47 - Volume
4,439,602 - Avg. Volume
4,536,009 - Market cap (intra-day)
24.574B - Beta (5Y monthly) 1.67
- PE ratio (TTM)
-- - EPS (TTM)
-15.35 - Earnings date 31 Oct 2024 - 4 Nov 2024
- Forward dividend & yield --
- Ex-dividend date --
- 1y target est
101.94
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
www.modernatx.com5,600
Full-time employees
31 December
Fiscal year ends
Healthcare
Sector
Biotechnology
Industry
Recent news: MRNA
View morePerformance overview: MRNA
Trailing total returns as of 26/09/2024, which may include dividends or other distributions. Benchmark is
.YTD return
1-year return
3-year return
5-year return
Compare to: MRNA
Select to analyse similar companies using key performance metrics; select up to four stocks.
Statistics: MRNA
View moreValuation measures
Market cap
24.57B
Enterprise value
17.36B
Trailing P/E
--
Forward P/E
--
PEG ratio (5-yr expected)
--
Price/sales (ttm)
4.90
Price/book (mrq)
2.10
Enterprise value/revenue
3.48
Enterprise value/EBITDA
--
Financial highlights
Profitability and income statement
Profit margin
-116.18%
Return on assets (ttm)
-15.42%
Return on equity (ttm)
-40.94%
Revenue (ttm)
5.05B
Net income avi to common (ttm)
-5.87B
Diluted EPS (ttm)
-15.35
Balance sheet and cash flow
Total cash (mrq)
8.49B
Total debt/equity (mrq)
10.84%
Levered free cash flow (ttm)
-2.35B